Urology practice change coming in the form of new alliances, accountable care organizations
May 1st 2012Many urologists are embarking on practice-changing moves, including forming new alliances with area hospitals or other practices and gearing up for participation in accountable care organizations (ACOs).
Neoadjuvant immunotherapy safe in advanced prostate cancer
May 1st 2012The autologous cellular immunotherapy sipuleucel-T (Provenge) can be safely given prior to radical prostatectomy, and in the neoadjuvant setting, the vaccine exerts a favorable effect on immune cells in prostate cancer tissue, specifically at the interface between the benign and malignant glands.
AUA 2012 Exhibit Hall Highlights
May 1st 2012This article features products and services from manufacturers that are exhibiting at the American Urological Association annual meeting in Atlanta. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.
Small urology practice model may pay big dividends
May 1st 2012There is certainly a perception that urologists are consolidating into larger and larger organizations, as well as an implication that the small practice model is no longer economically viable. Yet urologist John E. Bertini, Jr, MD, has been able to start, grow, and maintain a small, successful independent practice in downtown Houston for 25 years.
Investigational advanced prostate cancer treatment extends overall survival
May 1st 2012The investigational oral androgen receptor signaling inhibitor MDV3100 significantly extended survival by about 5 months versus placebo in men with metastatic castration-resistant prostate cancer (CRPC) who received prior treatment with docetaxel (Taxotere).
How large urology group practices improve care, lower costs
May 1st 2012To meet the challenges of a changing specialty, urologists across the country have organized into large, comprehensive integrated practices, often including physicians from other specialties, to deliver the highest quality care and service to patients with urologic diseases and conditions.
External beam radiation therapy more costly than brachytherapy, prostatectomy
May 1st 2012A retrospective long-term comparison of three prostate cancer treatment strategies revealed that treatment with external beam radiation therapy (EBRT) resulted in more long-term toxicities and higher treatment-related costs than prostatectomy and brachytherapy.
Analysis may explain exercise-prostate cancer progression link
May 1st 2012A recent study may have found the genetic mechanism behind the potential association between vigorous exercise and a reduced risk of prostate cancer progression and prostate cancer-specific mortality in men with localized disease.
Radiation analysis bolsters intensity-modulated radiation therapy as current standard
May 1st 2012A comparative effectiveness analysis of three techniques for delivering radiation therapy for the treatment of localized prostate cancer supports intensity-modulated radiation therapy (IMRT) as the current standard.
Atlanta extends Southern welcome to the American Urological Association 2012 annual meeting
May 1st 2012As the stopping point for the upcoming AUA 2012 annual meeting, May 19-23, Atlanta is sure to impress with its range of simple to sophisticated offerings in the arts, entertainment, culinary, and historical scenes.
Vaginal delivery increases incontinence risk up to 20 years later
April 25th 2012Compared with women who deliver via cesarean, women who deliver vaginally are 67% more likely to experience urinary incontinence up to 20 years after the birth and are almost three times as likely to be incontinent for more than 10 years, Swedish researchers report.
FDA: Label changes for finasteride expand list of adverse events
April 25th 2012The FDA has announced changes to the professional labels for finasteride, 5 mg (Proscar), and finasteride, 1 mg (Propecia), to expand the list of sexual adverse events reported to the FDA, as some of these events have been reported to continue after the drug is no longer being used.